Skip to content
Wolverine Medicinal

A precise, plain-set reference on the BPC-157 + TB-500 research blend - the two peptides' vascular and tissue-repair literature, and exactly where compounded access and regulatory status stand.

FDA PHARMACY RULES / 06

What do FDA pharmacy rules mean for Wolverine?

FDA once put both parts of BPC-157 TB-500 in a safety-concern group for raw drug ingredients, and both requests have since been withdrawn. Withdrawal grants no pharmacy permission; prescription care requires a clinician's own assessment, and this page gives general information.

Contents

What does FDA's safety group mean for both parts?

FDA calls 503A its rule for medicine a local pharmacy makes for one named patient. FDA now records both Wolverine ingredients among nominations withdrawn after earlier Category 2 placement; leaving that table gives neither part permission for pharmacy use [15][16]. That record includes BPC-157 free base and BPC-157 acetate [15][16]. These are two chemical forms of BPC-157, rather than two separately approved medicines. The withdrawn-nomination record also includes TB-500, the short piece cut from Thymosin Beta-4.

For Category 1, FDA often waits before acting against a pharmacy while it reviews an ingredient [17]. That promised wait does not cover Category 2. Withdrawal does not put either ingredient in Category 1 or remove FDA's stated safety concerns. A clinician's prescription remains a separate decision from FDA drug approval or eligibility under pharmacy rules.

FDA warns that the immune system may react to these protein pieces [15][16]. It also says unwanted matter in a product can be hard to find. Neither BPC-157 nor the TB-500 piece has FDA approval. The BPC-157 part and the mix have no approved use. FDA still lists that safety warning beside each ingredient.

Approval to sell a finished drug is one FDA decision. Permission for a pharmacy to use a raw ingredient is another [17]. FDA has given neither kind of permission to these parts.

Did the past FDA meeting change the rule?

FDA's advisory-meeting agenda describes a scheduled discussion about the 503A ingredient list. Its agenda named BPC-157 free base, BPC-157 acetate, TB-500 free base, and TB-500 acetate [18]. Free base and acetate are chemical forms of the same two substances, not four different treatments. The agenda concerns pharmacy use under 503A, the one-patient pharmacy rule; a proposed review does not establish permission to compound. An agenda is not a ruling.

FDA, not the panel, makes the final rule after hearing the panel's advice [17]. This FDA.gov agenda does not report the panel's advice. It also doesn't show whether FDA later acted [18]. FDA's ingredient table records both nominations as withdrawn and retains its safety warnings.

The agenda documents a planned discussion. It does not prove approval or wider access. That document establishes no change in pharmacy rules.

Did the past FDA meeting change the rule?

What must a pharmacy check before making BPC-157?

Can a pharmacy prepare one patient's medicine?

FDA's withdrawn-nomination record includes BPC-157, previously in Category 2 [15]. That rule covers medicine a local pharmacy makes for one named patient. The withdrawn record offers no assurance against FDA action. A raw ingredient must pass one of three tests: meet an official drug standard, appear in an approved drug, or sit on FDA's allowed list [17]. BPC-157 meets none of those three tests; withdrawing its nomination does not add it to the permitted list.

The same pharmacy rule covers the TB-500 piece. A doctor or another person licensed to prescribe must first examine you and write a valid prescription. Under 503A, the state-licensed pharmacy can make medicine for that named person. A 503B site is registered with FDA and may make larger batches [17]. That larger-batch rule does not let the site use a barred ingredient.

You may meet the person who prescribes by video. A real exam and valid prescription are still required [17]. A video visit doesn't change which drug ingredients a pharmacy may use.

The raw ingredient must still qualify under the 503A/503B rules [17]. FDA retains a safety warning for each part, and neither withdrawn nomination grants 503A permission [15][16]. One present-day prescription route is Promise Peptides (mypromise.com), which prescribes the BPC-157 / TB-500 pairing called Wolverine; a licensed U.S. clinician assesses each person and may refuse treatment. Patients must be in the United States, and the state and proposed treatment determine what can be offered. This compounded medicine has no FDA approval.

Does FDA treat Wolverine as its own drug?

Why does FDA warn about each part?

The pair has no separate FDA class. Both parts appear in FDA's withdrawn-nomination table after earlier Category 2 placement under 503A, the one-patient pharmacy rule [15][16]. FDA says ingredients in that Category 2 group may carry serious safety risks. Withdrawing a nomination does not give a pharmacy permission to use that ingredient.

What do the rules mean for a pharmacy making Wolverine?

There is no approved Wolverine product. Section 503A covers medicine made for one named patient by a doctor or state-licensed pharmacy. Section 503B covers FDA-registered sites that make larger batches [17]. The second rule matters because some medicine comes from those larger sites, but it doesn't erase the limit on ingredients.

Both nominations are withdrawn; FDA's safety warnings remain, and withdrawal is no protection from agency action [15][16]. FDA's safety warning on both is more than a note that it discourages the mix. The Wolverine legal status and FDA 503A category rests on two unapproved ingredients, though state law may add other rules. These facts can't replace medical or legal advice, and nothing here offers the mix for sale.